Engbaek F, Christensen S E, Jespersen B
Department of Clinical Chemistry, University Hospital of Aarhus, Denmark.
Clin Chem. 1989 Jan;35(1):93-7.
We evaluated an enzyme immunoassay (Novo BioLabs) for determination of hemoglobin A1c and measured the contribution of carbamylated hemoglobin to the hemoglobin A1c results obtained by HPLC for patients with chronic renal failure. The reference interval, determined for blood donors, was 0.035-0.050 (i.e., 3.5% to 5% of the total hemoglobin). For non-diabetic patients with chronic renal failure, on hemodialysis, the mean proportion of hemoglobin A1c was 0.038 (SD 0.0045); for umbilical cord blood it was 0.006-0.009. For diabetic patients with normal or near-normal renal function, results by enzyme immunoassay (y) and HPLC (x) correlated well (r = 0.83): y = 0.99x - 0.005. Added fetal hemoglobin or carbamylated hemoglobin did not interfere with enzyme immunoassay, but added carbamylated hemoglobin co-chromatographed with hemoglobin A1c. Measurements for patients with chronic renal failure, with or without diabetes, by enzyme immunoassay and by HPLC, were compared with measurements for patients with diabetes mellitus but no renal failure. Carbamylated hemoglobin contributed 0.019 to the hemoglobin A1c results obtained by HPLC for patients with chronic renal failure.
我们评估了一种用于测定糖化血红蛋白的酶免疫测定法（Novo BioLabs），并测量了慢性肾衰竭患者中氨甲酰化血红蛋白对通过高效液相色谱法（HPLC）获得的糖化血红蛋白结果的贡献。为献血者确定的参考区间为0.035 - 0.050（即占总血红蛋白的3.5%至5%）。对于接受血液透析的非糖尿病慢性肾衰竭患者，糖化血红蛋白的平均比例为0.038（标准差0.0045）；脐带血中的比例为0.006 - 0.009。对于肾功能正常或接近正常的糖尿病患者，酶免疫测定法（y）和HPLC法（x）的结果相关性良好（r = 0.83）：y = 0.99x - 0.005。添加的胎儿血红蛋白或氨甲酰化血红蛋白不干扰酶免疫测定法，但添加的氨甲酰化血红蛋白与糖化血红蛋白共色谱。将慢性肾衰竭患者（无论是否患有糖尿病）通过酶免疫测定法和HPLC法的测量结果与糖尿病但无肾衰竭患者的测量结果进行比较。氨甲酰化血红蛋白对慢性肾衰竭患者通过HPLC获得的糖化血红蛋白结果的贡献为0.019。
